Biochemistry And Microbial Sciences - Research Publications

Permanent URI for this collectionhttps://kr.cup.edu.in/handle/32116/27

Browse

Subject: search.filters.subject.GC-MS

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Antileukemic Activity of hsa-miR-203a-5p by Limiting Glutathione Metabolism in Imatinib-Resistant K562 Cells
    (MDPI, 2022-12-19T00:00:00) Singh, Priyanka; Yadav, Radheshyam; Verma, Malkhey; Chhabra, Ravindresh
    Imatinib has been the first and most successful tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), but many patients develop resistance to it after a satisfactory response. Glutathione (GSH) metabolism is thought to be one of the factors causing the emergence of imatinib resistance. Since hsa-miR-203a-5p was found to downregulate Bcr-Abl1 oncogene and also a link between this oncogene and GSH metabolism is reported, the present study aimed to investigate whether hsa-miR-203a-5p could overcome imatinib resistance by targeting GSH metabolism in imatinib-resistant CML cells. After the development of imatinib-resistant K562 (IR-K562) cells by gradually exposing K562 (C) cells to increasing doses of imatinib, resistant cells were transfected with hsa-miR-203a-5p (R+203). Thereafter, cell lysates from various K562 cell sets (imatinib-sensitive, imatinib-resistant, and miR-transfected imatinib-resistant K562 cells) were used for GC-MS-based metabolic profiling. L-alanine, 5-oxoproline (also known as pyroglutamic acid), L-glutamic acid, glycine, and phosphoric acid (Pi)�five metabolites from our data, matched with the enumerated 28 metabolites of the MetaboAnalyst 5.0 for the GSH metabolism. All of these metabolites were present in higher concentrations in IR-K562 cells, but intriguingly, they were all reduced in R+203 and equated to imatinib-sensitive K562 cells (C). Concludingly, the identified metabolites associated with GSH metabolism could be used as diagnostic markers. � 2022 by the authors.
  • No Thumbnail Available
    Item
    Pharmacological potential of serially extracted Solanum xanthocarpum fruit extracts and their phytochemical characterization
    (Taylor and Francis Ltd., 2022-05-23T00:00:00) Kumar, Shashank; Pandey, Abhay K.
    Pharmacological potential of serially extracted Solanum xanthocarpum fruit (SXF) extracts in terms of antioxidant, anticancer, and antibacterial activities was evaluated. Chemical characterization of the potent extract was done by HPLC, LC-MS-MS, and GC-MS techniques. In vitro antioxidant models, viz. hydroxyl radical scavenging, metal ion chelation, total antioxidant capacity, and ferric reducing antioxidant power, were used to assess the antioxidant potential of extract. Cytotoxicity of the SXF extracts was tested against prostate, ovary, and breast cancer cell lines (DU-145, IGR-OV-1, and MCF-7) using sulforhodamine (SRB) assay. The antibacterial potential was assessed against Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, Klebsiella pneumonia, and Escherichia coli bacteria. Results indicated potential pharmacological activities and the presence of pharmacologically active phytoconstituents in the SKF extracts. � 2022 Taylor & Francis Group, LLC.